08:34 AM EDT, 10/24/2025 (MT Newswires) -- Biogen (BIIB) said Friday it has been granted exclusive worldwide rights to biopharmaceutical company Vanqua Bio's preclinical drug candidate for inflammatory disorders.

Under the terms of the deal, Biogen will pay $70 million upfront to Vanqua, with up to $990 million in potential milestone payments, along with tiered royalties on potential net sales. Biogen also said it will lead all future development, manufacturing and commercialization efforts for the drug candidate.

The upfront payment will be considered an acquired in-process research and development expense in Q4, Biogen said.